A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Phase 1

Completed

• Conditions: Non-Small Cell Lung Cancer
• Interventions: Drug: BIIB022 With Paclitaxel and Carboplatin

• Registration Number: NCT00970580
• Lead Sponsor: Biogen

Brief Summary

The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-09-01
• Study First Submitted QC: 2009-09-01
• Study First Posted: 2009-09-02
• Study Start: 2009-10
• Primary Completion: 2011-09
• Study Completion: 2011-09
• Status Verified: 2011-11
• Last Update Submitted: 2013-09-12
• Last Update Posted: 2013-09-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• Age >/= 18 years old
• Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer
• ECOG Performance Status 0 or 1

Exclusion Criteria

• History of another primary cancer within 3 years
• Any prior or concurrent investigational or standard therapy for treatment of NSCLC
• Prior anti-IGF-1R therapy
• Unstable diabetes

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BIIB022 in Combination with Paclitaxel and Carboplatin	BIIB022 With Paclitaxel and Carboplatin	BIIB022 in Combination with Paclitaxel and Carboplatin

Primary Outcome Measures

Name	Time	Method
To evaluate the safety and tolerability of BIIB022 in combination with paclitaxel and carboplatin	6 months

Trial Locations

Locations (1)

Resesarch Site; 🇺🇸 Denver, Colorado, United States